Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy

<p>Abstract</p> <p>Background</p> <p>To test the hypothesis that point-of-care assays of platelet reactivity would demonstrate reduced response to antiplatelet therapy in patients who experienced Drug Eluting Stent (DES) ST whilst on dual antiplatelet therapy compared t...

Full description

Bibliographic Details
Main Authors: Dawkins Keith D, Morton Geraint, Petley Graham, Hobson Alex R, Curzen Nick P
Format: Article
Language:English
Published: BMC 2008-02-01
Series:Thrombosis Journal
Online Access:http://www.thrombosisjournal.com/content/6/1/1
_version_ 1811261714905169920
author Dawkins Keith D
Morton Geraint
Petley Graham
Hobson Alex R
Curzen Nick P
author_facet Dawkins Keith D
Morton Geraint
Petley Graham
Hobson Alex R
Curzen Nick P
author_sort Dawkins Keith D
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>To test the hypothesis that point-of-care assays of platelet reactivity would demonstrate reduced response to antiplatelet therapy in patients who experienced Drug Eluting Stent (DES) ST whilst on dual antiplatelet therapy compared to matched DES controls. Whilst the aetiology of stent thrombosis (ST) is multifactorial there is increasing evidence from laboratory-based assays that hyporesponsiveness to antiplatelet therapy is a factor in some cases.</p> <p>Methods</p> <p>From 3004 PCI patients, seven survivors of DES ST whilst on dual antiplatelet therapy were identified and each matched with two patients without ST. Analysis was performed using (a) short Thrombelastogram PlateletMapping™ (TEG) and (b) VerifyNow Aspirin and P2Y12 assays. TEG analysis was performed using the Area Under the Curve at 15 minutes (AUC15) as previously described.</p> <p>Results</p> <p>There were no differences in responses to aspirin. There was significantly greater platelet reactivity on clopidogrel in the ST group using the Accumetrics P2Y12 assay (183 ± 51 vs. 108 ± 31, p = 0.02) and a trend towards greater reactivity using TEG AUC15 (910 ± 328 vs. 618 ± 129, p = 0.07). 57% of the ST group by TEG and 43% of the ST cases by Accumetrics PRU had results > two standard deviations above the expected mean in the control group.</p> <p>Conclusion</p> <p>This study demonstrates reduced platelet response to clopidogrel in some patients with DES ST compared to matched controls. The availability of point-of-care assays that can detect these responses raises the possibility of prospectively identifying DES patients at risk of ST and manipulating their subsequent risk.</p>
first_indexed 2024-04-12T19:10:43Z
format Article
id doaj.art-f67f547d0dd042528fa7a9b52651abf1
institution Directory Open Access Journal
issn 1477-9560
language English
last_indexed 2024-04-12T19:10:43Z
publishDate 2008-02-01
publisher BMC
record_format Article
series Thrombosis Journal
spelling doaj.art-f67f547d0dd042528fa7a9b52651abf12022-12-22T03:19:54ZengBMCThrombosis Journal1477-95602008-02-0161110.1186/1477-9560-6-1Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapyDawkins Keith DMorton GeraintPetley GrahamHobson Alex RCurzen Nick P<p>Abstract</p> <p>Background</p> <p>To test the hypothesis that point-of-care assays of platelet reactivity would demonstrate reduced response to antiplatelet therapy in patients who experienced Drug Eluting Stent (DES) ST whilst on dual antiplatelet therapy compared to matched DES controls. Whilst the aetiology of stent thrombosis (ST) is multifactorial there is increasing evidence from laboratory-based assays that hyporesponsiveness to antiplatelet therapy is a factor in some cases.</p> <p>Methods</p> <p>From 3004 PCI patients, seven survivors of DES ST whilst on dual antiplatelet therapy were identified and each matched with two patients without ST. Analysis was performed using (a) short Thrombelastogram PlateletMapping™ (TEG) and (b) VerifyNow Aspirin and P2Y12 assays. TEG analysis was performed using the Area Under the Curve at 15 minutes (AUC15) as previously described.</p> <p>Results</p> <p>There were no differences in responses to aspirin. There was significantly greater platelet reactivity on clopidogrel in the ST group using the Accumetrics P2Y12 assay (183 ± 51 vs. 108 ± 31, p = 0.02) and a trend towards greater reactivity using TEG AUC15 (910 ± 328 vs. 618 ± 129, p = 0.07). 57% of the ST group by TEG and 43% of the ST cases by Accumetrics PRU had results > two standard deviations above the expected mean in the control group.</p> <p>Conclusion</p> <p>This study demonstrates reduced platelet response to clopidogrel in some patients with DES ST compared to matched controls. The availability of point-of-care assays that can detect these responses raises the possibility of prospectively identifying DES patients at risk of ST and manipulating their subsequent risk.</p>http://www.thrombosisjournal.com/content/6/1/1
spellingShingle Dawkins Keith D
Morton Geraint
Petley Graham
Hobson Alex R
Curzen Nick P
Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy
Thrombosis Journal
title Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy
title_full Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy
title_fullStr Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy
title_full_unstemmed Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy
title_short Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy
title_sort point of care platelet function assays demonstrate reduced responsiveness to clopidogrel but not aspirin in patients with drug eluting stent thrombosis whilst on dual antiplatelet therapy
url http://www.thrombosisjournal.com/content/6/1/1
work_keys_str_mv AT dawkinskeithd pointofcareplateletfunctionassaysdemonstratereducedresponsivenesstoclopidogrelbutnotaspirininpatientswithdrugelutingstentthrombosiswhilstondualantiplatelettherapy
AT mortongeraint pointofcareplateletfunctionassaysdemonstratereducedresponsivenesstoclopidogrelbutnotaspirininpatientswithdrugelutingstentthrombosiswhilstondualantiplatelettherapy
AT petleygraham pointofcareplateletfunctionassaysdemonstratereducedresponsivenesstoclopidogrelbutnotaspirininpatientswithdrugelutingstentthrombosiswhilstondualantiplatelettherapy
AT hobsonalexr pointofcareplateletfunctionassaysdemonstratereducedresponsivenesstoclopidogrelbutnotaspirininpatientswithdrugelutingstentthrombosiswhilstondualantiplatelettherapy
AT curzennickp pointofcareplateletfunctionassaysdemonstratereducedresponsivenesstoclopidogrelbutnotaspirininpatientswithdrugelutingstentthrombosiswhilstondualantiplatelettherapy